Search results
Aura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial Overview
GuruFocus.com via Yahoo Finance· 9 hours agoThe company's strategic focus remains on addressing significant unmet medical needs within ocular and urologic oncology, aiming to revolutionize treatment paradigms in these ...
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says Oppenheimer
TipRanks via Yahoo Finance· 1 day agoRisk and reward are the yin and yang of stock trading, the two essential yet opposing forces in...
Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy - Nature...
Nature· 3 days agoDual blockade therapy is currently being trialled for multiple tumour types, but efficacy is variable. Here, the authors use longitudinal proteomics profiling of 22 patients to develop a predictive model of therapy response.
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 2 days agoFurther, the companies are running a late-stage study in non-small cell lung cancer patients. One...
This 6% Yielding Dividend Stock Could Pump Up Your Passive-Income Stream
Motley Fool via Yahoo Finance· 2 days agoPre-commercial stage development tends to consume about half of this limited time frame....
CG Oncology (NASDAQ:CGON) Earns Buy Rating from HC Wainwright
ETF DAILY NEWS· 5 days agoCG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $75.00 ...
Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting
WTRF Wheeling· 4 days agoFollowing the podium presentation at AUA, these...
HC Wainwright Equities Analysts Decrease Earnings Estimates for Protara Therapeutics, Inc....
ETF DAILY NEWS· 2 days agoProtara Therapeutics, Inc. (NASDAQ:TARA – Free Report) – Equities researchers at HC Wainwright reduced their Q2 2024 earnings estimates for shares of Protara Therapeutics in a research note ...
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $8.50 Average Price Target from Brokerages
ETF DAILY NEWS· 6 days agoShares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have earned an average recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat.com ...
Fisher Asset Management LLC Acquires 127,228 Shares of Bristol-Myers Squibb (NYSE:BMY)
ETF DAILY NEWS· 4 days agoFisher Asset Management LLC increased its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 130.7% in the 4th quarter, according to the company in its most recent filing with the ...